The role of the growth factors IGF-1 and TGF beta 1 after hypoxic-ischemic brain injury.
D000818:Animals; D001253:Astrocytes / Q000378:metabolism; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology; D006801:Humans; D002534:Hypoxia, Brain / Q000503:physiopathology*; D007276:Injections, Intraventricular; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology; D018969:Insulin-Like Growth Factor Binding Proteins / Q000096:biosynthesis*; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage / Q000494:pharmacology* / Q000502:physiology*; D002546:Ischemic Attack, Transient / Q000503:physiopathology*; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000494:pharmacology* / Q000502:physiology*
D007328:Insulin; D018969:Insulin-Like Growth Factor Binding Proteins; D018696:Neuroprotective Agents; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D007334:Insulin-Like Growth Factor I